JP2015536950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536950A5 JP2015536950A5 JP2015540834A JP2015540834A JP2015536950A5 JP 2015536950 A5 JP2015536950 A5 JP 2015536950A5 JP 2015540834 A JP2015540834 A JP 2015540834A JP 2015540834 A JP2015540834 A JP 2015540834A JP 2015536950 A5 JP2015536950 A5 JP 2015536950A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cell lymphoma
- lymphoma
- ibrutinib
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 10
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 9
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 9
- 229960001507 ibrutinib Drugs 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010042971 T-cell lymphoma Diseases 0.000 claims 6
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000000090 biomarker Substances 0.000 claims 5
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 4
- 238000011319 anticancer therapy Methods 0.000 claims 4
- 230000036210 malignancy Effects 0.000 claims 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 3
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 3
- 229960002438 carfilzomib Drugs 0.000 claims 3
- 108010021331 carfilzomib Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940126638 Akt inhibitor Drugs 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 2
- 229940125431 BRAF inhibitor Drugs 0.000 claims 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 229940122680 Demethylase inhibitor Drugs 0.000 claims 2
- 239000012824 ERK inhibitor Substances 0.000 claims 2
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 2
- 102000042834 TEC family Human genes 0.000 claims 2
- 108091082333 TEC family Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims 2
- 208000028774 intestinal disease Diseases 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000037922 refractory disease Diseases 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722107P | 2012-11-02 | 2012-11-02 | |
| US61/722,107 | 2012-11-02 | ||
| US201361785868P | 2013-03-14 | 2013-03-14 | |
| US61/785,868 | 2013-03-14 | ||
| PCT/US2013/068132 WO2014071231A1 (en) | 2012-11-02 | 2013-11-01 | Tec family kinase inhibitor adjuvant therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018179447A Division JP2019031506A (ja) | 2012-11-02 | 2018-09-25 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015536950A JP2015536950A (ja) | 2015-12-24 |
| JP2015536950A5 true JP2015536950A5 (OSRAM) | 2016-12-22 |
Family
ID=50628113
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540834A Pending JP2015536950A (ja) | 2012-11-02 | 2013-11-01 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
| JP2018179447A Ceased JP2019031506A (ja) | 2012-11-02 | 2018-09-25 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
| JP2020120047A Pending JP2020183413A (ja) | 2012-11-02 | 2020-07-13 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018179447A Ceased JP2019031506A (ja) | 2012-11-02 | 2018-09-25 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
| JP2020120047A Pending JP2020183413A (ja) | 2012-11-02 | 2020-07-13 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9717731B2 (OSRAM) |
| EP (1) | EP2914263A4 (OSRAM) |
| JP (3) | JP2015536950A (OSRAM) |
| KR (1) | KR20150080592A (OSRAM) |
| CN (2) | CN111329989A (OSRAM) |
| AU (3) | AU2013337663A1 (OSRAM) |
| BR (1) | BR112015010059A2 (OSRAM) |
| CA (1) | CA2890111A1 (OSRAM) |
| CL (1) | CL2015001147A1 (OSRAM) |
| CR (1) | CR20150242A (OSRAM) |
| DO (1) | DOP2015000098A (OSRAM) |
| EA (1) | EA201590822A1 (OSRAM) |
| HK (1) | HK1214508A1 (OSRAM) |
| IL (1) | IL238548A0 (OSRAM) |
| MX (2) | MX2015005633A (OSRAM) |
| NI (1) | NI201500062A (OSRAM) |
| PE (1) | PE20151604A1 (OSRAM) |
| PH (1) | PH12015500985A1 (OSRAM) |
| SG (1) | SG11201503459SA (OSRAM) |
| TN (1) | TN2015000170A1 (OSRAM) |
| TW (1) | TW201427664A (OSRAM) |
| WO (1) | WO2014071231A1 (OSRAM) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| EA031737B1 (ru) | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
| JP6068340B2 (ja) | 2010-08-10 | 2017-01-25 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | Ｂｔｋ阻害剤のベシル酸塩 |
| HUE027317T2 (en) | 2010-10-26 | 2016-10-28 | Mars Inc | Boronates as arginase inhibitors |
| ES2635713T3 (es) | 2010-11-01 | 2017-10-04 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| NZ710636A (en) | 2010-11-01 | 2017-02-24 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
| JP5957003B2 (ja) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | 変異体選択的ｅｇｆｒ阻害剤およびその使用 |
| US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
| ES2698298T3 (es) | 2012-03-15 | 2019-02-04 | Celgene Car Llc | Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico |
| ES2880109T3 (es) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico |
| EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| EP2914263A4 (en) | 2012-11-02 | 2016-04-27 | Pharmacyclics Inc | ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| PE20151274A1 (es) | 2013-02-08 | 2015-09-12 | Celgene Avilomics Res Inc | Inhibidores de erk y sus usos |
| CN105764502A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群及其类似物及衍生物的治疗益处的组合方法 |
| EP3027192A4 (en) * | 2013-08-02 | 2017-03-22 | Pharmacyclics, LLC | Methods for the treatment of solid tumors |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| EP3060251A4 (en) * | 2013-10-25 | 2017-12-06 | Pharmacyclics LLC | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| US10314842B2 (en) * | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2015187848A1 (en) * | 2014-06-04 | 2015-12-10 | Sampath Deepa | Hdac inhibitor and btk inhibitor combinations |
| US20150361504A1 (en) * | 2014-06-13 | 2015-12-17 | Pharmacyclics Llc | Biomarker for predicting response of cll to treatment with a btk inhibitor |
| WO2016010961A1 (en) * | 2014-07-15 | 2016-01-21 | Abbvie Inc. | Enzyme occupancy assay |
| WO2016015044A1 (en) * | 2014-07-25 | 2016-01-28 | Northeastern University | Biopolymer-nanoparticle composite implant for tumor cell tracking |
| WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
| WO2016044774A1 (en) * | 2014-09-18 | 2016-03-24 | Pharmacyclics Llc | Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor |
| JP2017536403A (ja) * | 2014-12-04 | 2017-12-07 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | デルタ肝炎ウイルス感染の治療 |
| US20180098972A1 (en) | 2015-01-26 | 2018-04-12 | Children's Medical Center Corporation | Treatment of infectious diseases |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| WO2016138542A1 (en) * | 2015-02-28 | 2016-09-01 | Cyprus Therapeutics, Inc. | Methods for inhibiting tumors and drug resistance |
| TWI697329B (zh) | 2015-04-13 | 2020-07-01 | 日商第一三共股份有限公司 | 血液癌症治療用之醫藥及其用途 |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| CA2982452A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| AU2016270658B2 (en) | 2015-05-29 | 2021-08-12 | Alexion Pharmaceuticals, Inc. | Cerdulatinib for the treatment of B-cell malignancies |
| US11554138B2 (en) | 2015-07-16 | 2023-01-17 | The University Of Hong Kong | Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy |
| AU2016303659A1 (en) * | 2015-07-31 | 2018-02-22 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| WO2017027829A1 (en) * | 2015-08-12 | 2017-02-16 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating myeloma |
| PT3368541T (pt) * | 2015-10-30 | 2020-07-06 | Calithera Biosciences Inc | Composições e métodos para inibição da atividade da arginase |
| ES2959692T3 (es) | 2015-12-04 | 2024-02-27 | Alexion Pharma Inc | Cerdulatinib y venetoclax para tratar linfoma no Hodgkin |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| SMT202100335T1 (it) | 2016-02-19 | 2021-07-12 | Eiger Biopharmaceuticals Inc | Trattamento dell'infezione da virus dell'epatite con interferone lambda |
| EA201892836A1 (ru) | 2016-06-29 | 2019-07-31 | Принсипиа Биофарма Инк. | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением |
| EP3318276A1 (en) * | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| CN106405086A (zh) * | 2016-09-21 | 2017-02-15 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
| CN110139669A (zh) | 2016-11-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | T细胞疗法和btk抑制剂的组合疗法 |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| ES2970715T3 (es) | 2016-12-22 | 2024-05-30 | Prec Pharmaceuticals Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| CN108732280B (zh) * | 2017-04-18 | 2022-07-08 | 广东东阳光药业有限公司 | 一种分离检测盐酸达卡他韦及其光学异构体的方法 |
| WO2019014684A1 (en) * | 2017-07-14 | 2019-01-17 | Ohio State Innovation Foundation | EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS |
| WO2019063958A1 (en) | 2017-09-27 | 2019-04-04 | The University Of York | BIOCONJUGATION OF POLYPEPTIDES |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| BR112020022185A2 (pt) | 2018-05-03 | 2021-02-02 | Juno Therapeutics Inc | terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase |
| TW202014412A (zh) | 2018-05-04 | 2020-04-16 | 美商普托拉製藥有限公司 | 賽度替尼(cerdulatinib)之固體型式 |
| CN111110685A (zh) * | 2018-10-31 | 2020-05-08 | 正大天晴药业集团股份有限公司 | 一种含伊布替尼的药物组合物及其应用 |
| KR20220061149A (ko) * | 2019-09-09 | 2022-05-12 | 더 칠드런스 호스피탈 오브 필라델피아 | Clec16A 기능장애 또는 손실과 관련된 장애의 치료를 위한 조성물 및 방법 |
| MX2022004427A (es) | 2019-10-14 | 2022-07-12 | Principia Biopharma Inc | Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo. |
| WO2021093790A1 (en) * | 2019-11-11 | 2021-05-20 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| MX2022009009A (es) | 2020-01-22 | 2022-08-15 | Principia Biopharma Inc | Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo. |
| US20230158030A1 (en) * | 2020-04-10 | 2023-05-25 | Ohio State Innovation Foundation | Methods and composition for treatment of covid-19 illness requiring hospitalization |
| US20230286934A1 (en) * | 2020-06-08 | 2023-09-14 | Icahn School Of Medicine At Mount Sinai | Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections |
| KR20240169633A (ko) * | 2022-04-05 | 2024-12-03 | 코버스 파마슈티칼스, 인크. | Th1 세포 활성을 증가시키기 위한 itk 저해제 |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2025071560A1 (en) * | 2023-09-28 | 2025-04-03 | Rutgers, The State University Of New Jersey | Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof |
| WO2024206869A2 (en) * | 2023-03-30 | 2024-10-03 | Board Of Regents, The University Of Texas System | Combination of hpk1 inhibitor and axl inhibitor in cancer therapy |
| WO2025085889A1 (en) * | 2023-10-20 | 2025-04-24 | Corvus Pharmaceuticals, Inc. | Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1240899A3 (en) | 1996-01-23 | 2004-05-19 | Ribapharm, Inc. | Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections |
| EP1254911A1 (en) | 1996-10-16 | 2002-11-06 | ICN Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
| US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
| AU1096400A (en) | 1998-09-28 | 2000-04-17 | Boston Medical Center Corporation | Determining resistance to treatment for hepatitis c virus |
| US6824768B2 (en) | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
| CO5241354A1 (es) | 1999-04-19 | 2003-01-31 | Schering Corp | Terapia de combinacio para vhc |
| EP1227844A2 (en) | 1999-10-29 | 2002-08-07 | Pharmacyclics, Inc. | Compositions for treating atheroma and neoplastic tissue |
| NZ520055A (en) | 2000-03-09 | 2004-06-25 | Schering Corp | HIV immune adjuvant theraphy |
| WO2001088199A2 (en) | 2000-05-18 | 2001-11-22 | Genetics Institute, Llc | Identification and modulationof of a t helper-1 and t helper-2 cells |
| AU2002213343A1 (en) | 2000-10-18 | 2002-04-29 | Schering Corporation | Ribavirin-pegylated interferon alfa HCV combination therapy |
| US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
| GB0116249D0 (en) | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
| AU2003251900B2 (en) | 2002-07-15 | 2008-12-18 | President And Fellows Of Harvard College | Methods and compositions for modulating T helper (Th) cell development and function |
| EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| US20070032457A1 (en) | 2003-05-16 | 2007-02-08 | Blatt Lawrence M | Combination therapy for cancer treatment |
| CN1886156A (zh) | 2003-09-30 | 2006-12-27 | 特莱索恩儿童健康研究院 | 免疫治疗方法 |
| CA2628397C (en) | 2005-11-04 | 2013-08-20 | Novartis Vaccines And Diagnostics S.R.L. | Changing th1/th2 balance in split influenza vaccines with adjuvants |
| US20090197853A1 (en) | 2005-11-16 | 2009-08-06 | Pharmacyclics, Inc. | Methods and compositions of treating cancer |
| GB0605521D0 (en) | 2006-03-18 | 2006-04-26 | Isis Innovation | Adjuvant |
| EP2054076A2 (en) | 2006-08-21 | 2009-05-06 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
| EP2529621B1 (en) * | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| MX2010005244A (es) | 2007-11-12 | 2010-10-25 | Theraclone Sciences Inc | Composiciones y métodos para la terapia y el diagnóstico de influenza. |
| GB0805356D0 (en) | 2008-03-25 | 2008-04-30 | Isis Innovation | Vaccine adjuvant composition |
| CN102036658A (zh) | 2008-05-23 | 2011-04-27 | 香港大学 | 治疗流感的联合疗法 |
| US20110218512A1 (en) | 2008-06-03 | 2011-09-08 | Aethlon Medical, Inc. | Enhanced antiviral therapy methods and devices |
| JP2012503619A (ja) | 2008-09-26 | 2012-02-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ |
| SG172227A1 (en) | 2008-12-18 | 2011-07-28 | Hoffmann La Roche | Biomarkers for hcv treatment response |
| JP2012517478A (ja) | 2009-02-12 | 2012-08-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤 |
| TW201106969A (en) | 2009-04-20 | 2011-03-01 | Genentech Inc | Adjuvant cancer therapy |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| EA031737B1 (ru) * | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
| GB2481611A (en) | 2010-06-30 | 2012-01-04 | Statoil Asa | Test cell for well fluid assessment |
| JP2014505666A (ja) * | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | 癌治療のための降圧剤の組成物および使用 |
| JP2014527036A (ja) | 2011-06-27 | 2014-10-09 | ザ ジャクソン ラボラトリー | 癌および自己免疫疾患の処置のための方法および組成物 |
| WO2013036994A1 (en) | 2011-09-16 | 2013-03-21 | Biota Scientific Management Pty Ltd | Compounds for the treatment of hcv |
| WO2013085893A1 (en) | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| US9296753B2 (en) * | 2012-06-04 | 2016-03-29 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
| EP2914263A4 (en) | 2012-11-02 | 2016-04-27 | Pharmacyclics Inc | ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR |
-
2013
- 2013-11-01 EP EP13850097.0A patent/EP2914263A4/en not_active Withdrawn
- 2013-11-01 CN CN202010271248.7A patent/CN111329989A/zh active Pending
- 2013-11-01 JP JP2015540834A patent/JP2015536950A/ja active Pending
- 2013-11-01 MX MX2015005633A patent/MX2015005633A/es unknown
- 2013-11-01 BR BR112015010059A patent/BR112015010059A2/pt not_active Application Discontinuation
- 2013-11-01 EA EA201590822A patent/EA201590822A1/ru unknown
- 2013-11-01 AU AU2013337663A patent/AU2013337663A1/en not_active Abandoned
- 2013-11-01 TW TW102139881A patent/TW201427664A/zh unknown
- 2013-11-01 KR KR1020157014129A patent/KR20150080592A/ko not_active Withdrawn
- 2013-11-01 WO PCT/US2013/068132 patent/WO2014071231A1/en not_active Ceased
- 2013-11-01 US US14/070,420 patent/US9717731B2/en active Active
- 2013-11-01 SG SG11201503459SA patent/SG11201503459SA/en unknown
- 2013-11-01 CN CN201380065469.7A patent/CN104994858A/zh active Pending
- 2013-11-01 HK HK16102454.7A patent/HK1214508A1/zh unknown
- 2013-11-01 PE PE2015000592A patent/PE20151604A1/es not_active Application Discontinuation
- 2013-11-01 CA CA2890111A patent/CA2890111A1/en not_active Abandoned
-
2014
- 2014-03-05 US US14/198,559 patent/US20140371241A1/en not_active Abandoned
-
2015
- 2015-04-30 DO DO2015000098A patent/DOP2015000098A/es unknown
- 2015-04-30 CL CL2015001147A patent/CL2015001147A1/es unknown
- 2015-04-30 IL IL238548A patent/IL238548A0/en unknown
- 2015-04-30 NI NI201500062A patent/NI201500062A/es unknown
- 2015-05-04 PH PH12015500985A patent/PH12015500985A1/en unknown
- 2015-05-04 TN TNP2015000170A patent/TN2015000170A1/fr unknown
- 2015-05-04 MX MX2021003018A patent/MX2021003018A/es unknown
- 2015-05-08 CR CR20150242A patent/CR20150242A/es unknown
-
2017
- 2017-07-14 US US15/650,830 patent/US20180071293A1/en not_active Abandoned
-
2018
- 2018-09-21 AU AU2018233032A patent/AU2018233032B2/en not_active Ceased
- 2018-09-25 JP JP2018179447A patent/JP2019031506A/ja not_active Ceased
-
2019
- 2019-05-21 US US16/418,590 patent/US20200147084A1/en not_active Abandoned
-
2020
- 2020-07-13 JP JP2020120047A patent/JP2020183413A/ja active Pending
- 2020-08-21 AU AU2020220205A patent/AU2020220205A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536950A5 (OSRAM) | ||
| EP4400173A3 (en) | Anti-sirp alpha antibodies | |
| TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| JP2013533232A5 (OSRAM) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2008507530A5 (OSRAM) | ||
| JP2016506908A5 (OSRAM) | ||
| JP2015134825A5 (OSRAM) | ||
| JP2018508469A5 (OSRAM) | ||
| WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2013527232A5 (OSRAM) | ||
| JP2011079858A5 (OSRAM) | ||
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| HK1222297A1 (zh) | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 | |
| CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
| WO2014165412A3 (en) | Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
| JP2006500346A5 (OSRAM) | ||
| WO2009140675A3 (en) | Combination therapy with pm00104 and another antitumor agent | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| EP4410373A3 (en) | Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene | |
| CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| WO2008088855A3 (en) | Gene polymorphisms as predictors of tumor progression and their use in cancer therapy | |
| WO2014087240A3 (en) | Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis | |
| WO2019070161A3 (en) | Articles and methods directed to personalized therapy of cancer |